PATENT CLAIM ANALYSIS

Application Number: 16270206
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "432000"]

Abstract:
Provided herein is a method of treating a central nervous system disorder in a patient in need thereof, wherein the central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia. The method comprises orally administering an initial dose of between 75 mg and 300 mg xanomeline and an initial dose of between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. Provided that the patient tolerates said administration, an increased dose of trospium chloride and an increased dose of xanomeline are orally administering to the patient, wherein the increased dose of trospium chloride is greater than the initial dose of the trospium chloride, and wherein the increased dose of xanomeline is greater than the initial dose of the xanomeline.

Claim (Index 15):
The method of  claim 1 , wherein the increased dose of trospium chloride is between 20 mg and 200 mg administered to the patient during the 24-hour period.

Metadata:
- Claim Count in Document: 22.0
- Percentile: 99.0
- Lexical Diversity: 2.47458
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15378796', '15400108', '15260996', '12934140', '14290123']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7375642446601898
- 35 USC 102 Novelty (BERT): 0.5998370092177907
- Combined Prediction Score: 0.7237915211159499
- Mean Citation Score: 324.13161
- Max Citation Score: 538.4479
- Similarity Product: 483.8461602712333

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test